natgillin/translations-raw huggingface dataset:
providing a trisaccharide and dissolving it in a solvent, wherein the trisaccharide is raffinose, melezitose or maltotriose; and esterifying all OH-groups of the trisaccharide, wherein at least one of the OH-groups of the trisaccharide is reacted with an anionic agent, wherein the trisaccharide is esterified with on average one sulphate ester or phosphate ester group and ten identical fatty acid ester groups per trisaccharide or with two sulphate or phosphate ester groups and nine identical fatty acid ester groups per trisaccharide, wherein the fatty acid is a straight, branched, saturated or unsaturated fatty acid with a chain length of between 4 to 20 carbon atoms. 
Postupak dobivanja trisaharidnog derivata u skladu s bilo kojim od patentnih zahtjeva 17-19, naznačen time što se sastoji u koracima: a) osiguravanja trisaharida i njegovog otapanja u otapalu, gdje je trisaharid rafinoza, melezitoza ili maltotrioza; 1 b) esterificiranju svih OH-skupina u trisaharidu, gdje najmanje jedna od OH-skupina u trisaharidu reagira s anionskim sredstvom, gdje se trisaharid esterificira s prosječno jednom sulfatnom ili fosfatnom esterskom skupinom i deset istovjetnih esterskih skupina masnih kiselina po trisaharidu ili s dvije sulfatne ili fosfatne esterske skupine i devet istovjetnih esterskih skupina masnih kiselina po trisaharidu, gdje je masna
applying an adhesive substance to the back surface of the vacuum formed sheet. The method of claim 1, wherein the plastic sheet is manufactured from a polyvinyl chloride (PVC), styrene or other rigid plastic material. 
Postupak proizvodnje oglasne ploče (100) kao što je navedeno u zahtjevu 1, naznačen time da je plastična folija (302) proizvedena od polivinil klorida (PVC), stirena ili drugog čvrstog plastičnog materijala.
A method according to claim 15 comprising co-administering at least one other antiviral agent. 
Primjena prema patentnom zahtjevu 12, naznačena time što režim liječenja ili lijek dalje sadrže najmanje jedno različito antivirusno sredstvo.
The method of claim 1, further comprising comparing frequency band values to identify the breath candidate using the processing apparatus. The method of claim 1, further comprising identifying, using the processing apparatus, a time at which the sound signal in at least one of the separated bands of the more than two frequency bands has risen a predetermined proportion from a predetermined threshold, and optionally wherein the predetermined threshold is at least one of: 
Postupak kao što je navedeno u zahtjevu 1, dalje sadržeći identifikaciju vremena u kojem je signal u barem jednom odvojenom pojasu narastao predodređeni dio od predodređenog praga, i opcionalno pri čemu je prag u odvojenom pojasu ovisan o barem parametru drugog odvojenog pojasa ili o prethodno korištenom pragu i/ili pri čemu je prag funkcija točke minimuma ili prekretnice.
introducing the fumigated intake air into a combustion chamber in the engine and compressing the intake air; 
- < unos isušenog ulaznog zraka u komoru za izgaranje u motoru i komprimiranje ulaznog zraka;
The composition of claims 1 to 15, comprising 10-20%, preferably 12-21%, preferably 15% medium chain fatty acid salt preferably sodium octanoate, 5-10%, preferably 10% PVP-12, and wherein the hydrophobic medium comprises 20-80%, preferably 30-70% triglyceride preferably glyceryl tricaprylate or glyceryl tributyrate or castor oil or a mixture thereof, 3-10% surfactants, preferably 6% glyceryl monocaprylate and polyoxyethylene sorbitan monooleate and about 1% water and wherein the octreotide is present at an amount of less than 33%, or less than 25%, or less than 10 %, or less than 1% or less than 0.1%. 
Pripravak prema zahtjevima 1 do 15, naznačen time da sadrži 10-20%, poželjno 12-21%, poželjno 15% soli masne kiseline srednjeg lanca poželjno natrijevog oktanoata, 5-10%, poželjno 10% PVP-12, te pri čemu hidrofobni medij sadrži 20-80%, poželjno 30-70% triglicerida poželjno gliceril trikaprilat ili gliceril tributirat ili ricinusovo ulje ili njihovu smjesu, 3-10% surfaktanata, poželjno 6% gliceril monokaprilata i polioksietilen sorbitan monooleata i oko HR P20170929 T1 1% vode i pri čemu je oktreotid prisutan u količini od manje od 33%, ili manje od 25%, ili manje od 10 %, ili manje od 1% ili manje od 0.1%.
The process according to any one of the preceding claims, characterised in that the surface-reacted calcium carbonate has a specific surface area of from 1 m2/g to 200 m2/g, preferably 40 m2/g to 175 m2/g, more preferably 50 to 145 m2/g, especially preferably 60 m2/g to 90 m2/g, most preferably 70 m2/g to 80 m2/g, measured using nitrogen and the BET method according to ISO 9277. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da površinski reagirani kalcijev karbonat ima specifičnu površinu od 1 m?/g do 200 m'/g, poželjno 40 m"/g do 175 m"/g, poželjnije 50 do 145 m'/g, naročito poželjno 60 m'/g do 90 m/g, najpoželjnije 70 m"/g do 80 m'/g, mjereno pomoću dušika i BET postupkom prema ISO 9277.
The present invention relates to mutant G protein coupled receptors (GPCRs) and methods for selecting those with increased stability. 
IA Metoda za odabir receptora vezanog na G-proteine (GPCR) s većom konformacijskom stabilnosti, metoda naznačena time da obuhvaća
effecting the hydrolysis of a compound of formula (II): 
(a) hidrolizu spoja formule (II): oO Ng R
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) cyprodinil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, le kao komponentu (B) fluopiram.
The method according to claims 17 or 18, characterized in that the coating yarn or yarns of said elastomer yarn (2a) used to provide said second rows of knitting (2) is made of natural or polyamide fibers. 
Postupak prema zahtjevu 17 ili 18, naznačen time, da je prevučeni konac, odnosno da su prevučeni konci elastomernog konca, upotrijebljenog za izradu parnih redova (2) izrađeni iz prirodnih ili poliamidnih vlakana.
The mixture was extracted 3× with hexane; the combined organic layers were washed 3× with H2O, 2× with aq Na2CO3 and 2× with brine before drying over Na2SO4. 
Smjesa je ekstrahirana 3x sa heksanom; spojeni organski slojevi su isprani 3x sa HO, 2x sa vodenom otopinom Na,CO; i 2x sa fiziološkom otopinom prije sušenja preko NaoSO,.
Non-limiting examples of this category include compounds having the formula: 
PATENTNI ZAHTJEVI Spoj s formulom: a OH
For example, if in the obtained compound of formula (I), R" represents an alkyl group or R"' represents a -Oalkyl group, the desired compound of formula (I) in which R" represents a hydrogen atom or R"' represents a -OH group can be obtained by saponifying the obtained compound of formula (I). 
Kao primjer, ako u dobivenom spoju formule (1), R'" predstavlja alkilnu skupinu ili R'""' predstavlja -Oalkilnu skupinu, željeni spoj formule (I) gdje R" predstavlja vodikov atom ili R'"' predstavlja -OH skupinu može se dobiti saponifikacijom dobivenog spoja formule (1).
The use of claim 9, wherein the antibody or antigen-binding fragment thereof specifically binds to human, rat, and mouse VEGF. 
Uporaba prema patentnom zahtjevu 10, naznačena time, da se protutijelo ili njegov ulomak koji veže antigen specifično veže na ljudski, štakorski i mišji VEGF.
wherein C6-10aryl is substituted with; and the heteroaryl is optionally substituted with; one substituent selected from the group consisting of fluoro, chloro, bromo, C1-4alkyl, cyano, and trifluoromethyl; 
pri čemu je C6-10aril supstituiran; i heteroaril je opciono supstituiran sa; jednim supstituentom izabranim iz grupe koju čine fluoro, kloro, bromo, C1-4alkil, cijano, i trifluorometil;
methyl substituted with i) C3-C5 cycloalkyl; ii) phenoxy; or iii) a phenyl and a second substituent selected from the group consisting of: methyl, halo and methoxy; 
– metil, supstituiran s i) C3-C5 cikloalkilom; ii) fenoksi; ili iii) fenilom i drugim supstituentom, kojeg se bira iz skupine koju čine: metil, halogen i metoksi;
time deinterleaving the extracted constellation values corresponding to the L1 signaling data by serially writing the extracted constellation values corresponding to the L1 signaling data into a memory in a row direction and reading the written constellation values corresponding to the L1 signaling data from the memory in a diagonal direction according to the L1 TI mode information, wherein a number of rows of the memory is equal to the time interleaving depth, wherein a number of columns of the memory is equal to a quotient resulting from dividing a number of constellation values corresponding to the L1 signaling data by the time interleaving depth, and wherein the time interleaving depth is equal or larger than a minimum number of OFDM symbols required for carrying an Layer 1 block including the L1 signaling data; 
raspletanje vremena izlučenih konstelacijskih vrijednosti koje odgovaraju signalnom podatku L1 serijskim ispisivanjem izlučenih konstelacijskih vrijednosti koje odgovaraju signalnom podatku L1 u memoriji u smjeru retka i čitanju zapisanih konstelacijskih vrijednosti koje odgovaraju signalnom podatku L1 iz memorije u dijagonalnom smjeru prema informaciji L1 TI vrste, pri čemu je broj redaka u memoriji jednak dubini umetanja vremena, pri čemu je broj stupaca memorije jednak kvocijentu koji je rezultat dijeljenja broja konstelacijskih vrijednosti koje odgovaraju signalnom podatku L1 s dubinom umetanja vremena, i pri čemu je dubina umetanja vremena jednaka ili veća od najmanjeg broja OFDM simbola potrebnih za prijenos L1 bloka uključujući signalni podatak L1;
shows the glucose and lactate concentration in the supernatant. 
prikazuje koncentracije glukoze i laktata u supernatantu.
For example the hydroxy protecting group, Pg, in a compound of the Formula XI as hereinbefore described in Reaction Scheme 1 is removed to give the compound of the Formula XIII: The protecting group Pg may be removed from the compound of Formula XI using conventional techniques. 
Na primjer, uklanjanjem hidroksi zaštitne skupine, Pg, u spoju prikazanom Formulom XI u skladu sa ranijim opisom u Reakcijskoj Shemi 1, dobije se spoj prikazan Formulom XIII: Zaštitna skupina Pg može se ukoniti iz spoja prikazanog Formulom XI upotrebom konvencionalnih tehnika.
The composition or use of any one of the preceding claims, further comprising at least one compound selected from the group consisting of amiloride, amlexanox, bezafibrate, carbamazepine, gabapentin, ibudilast, leflunomide, losartan, methimazole, naproxen, nicardipine, nicergoline, perhexiline, pyrimethamine, sulodexide and telmisartan, or salts or sustained release formulations thereof. The composition or use of any one of the preceding claims, further comprising at least one compound selected from the group consisting of levodopa, pergolide, cabergoline, lisuride, pramipexole, ropinirole, apomorphine, selegiline, rasagiline, tolcapone, entacapone, clozapine, desipramine, citalopram, nortriptyline, paroxetine, atomoxetine, venlafaxine, amantadine, donepezil, rivastigmine and memantine, or salts or sustained release formulations thereof. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što se najmanje jedan preteča dopamina bira iz skupine koju čine levodopa i melevodopa, ili njihove soli, ili njihove formulacije s produljenim otpuštanjem, najmanje jedan agonist dopaminskih receptora se bira iz skupine koju čine talipeksol, piribedil, rotigotin, bromokriptin, pergolid, kabergolin, lisurid, pramipeksol, ropinirol ili apomorfin, ili njihove soli, ili njihove formulacije s produljenim otpuštanjem, a najmanje jedan inhibitor enzima koji metaboliziraju dopamin se bira iz skupine koju čine selegilin i rasagilin, ili njihove soli, ili njihove formulacije s produljenim otpuštanjem.
methyl, or a polyfunctional ester, e.g. 
metil, ili estera s više funkcionalnih skupina, npr.
When the amine-protecting group is an acidolytically removable group, it is conveniently deprotected by the use of a strong acid, such as trifluoroacetic acid optionally in the presence of dichloromethane. 
Kada je amino- zaštitna skupina acidolitički uklonjiva amino- zaštitna skupina, tada je deprotektiranje najbolje upotrebom jake kiseline, kao što je triflor octena kiselina po izboru u prisutnosti diklormetana.
an activity portion that modulates transcription within the target DNA, wherein the site of modulated transcription within the target DNA is determined by the DNA-targeting RNA. 
2. > Postupak modificiranja ciljane DNK, naznačen time, da postupak obuhvaća stavljanje u doticaj ciljane DNK s kompleksom koji obuhvaća sljedeće:
converting Compound 27 to Compound 14: 
(c) prevođenju Spoja 27 u Spoj 14:
A developer supply container according to Claim 3, wherein with increase of a volume of a chamber of said pump portion (2b), the pressure at least in said developer discharging chamber (3h) becomes negative. 
Spremnik za nadopunjavanje razvijača u skladu s patentnim zahtjevom 3, naznačen time što s povećavanjem volumena komore navedenog crpnog dijela (2b) tlak u najmanju ruku u navedenoj komori za ispuštanje razvijača (3h) postaje negativan.
In still another embodiment of aspect 3 to be in particular emphasized, the present invention refers to an acid addition salt of (E)-N-hydroxy-3-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-1H-pyrrol-3-yl]-acrylamide with any acid selected from the group consisting of phosphoric acid, sulphuric acid and methanesulphonic acid, or a hydrate thereof. 
HR P20120399 T1 Spoj u skladu s patentnim zahtjevom 1, naznačen time što je kiselinska adicijska sol (£)-3-[1-(4- dimetilaminometilbenzensulfonil)-1 H-pirol-3-11]-N-hidroksiakrilamida s metansulfonskom kiselinom, ili njegov hidrat.
21) are underlined. FIGS. 
(21) Broj predmeta:
at least a subset of said locking tumblers comprising a body part (206a) and an integral key sensing part (206b) for engagement with a longitudinal code pattern of an associated key (100), said body part being mounted in an associated chamber (208) in said key plug for elevational movement therein along a tumbler axis in parallel to the axis of ssaid associated chamber, 
- - barem podskup navedenih čepića za zaključavanje sadrži dio kućišta (2064) 1 integralni dio za raspoznavanje ključa (206b) koji surađuje sa uzdužnim kodnim uzorkom pripadajućeg ključa (100), a navedeni dio kućišta je postavljen u odgovarajuću komoru (208) u navedenom ulošku za ključ radi vertikalnog pomicanja uzduž osi čepića paralelno s osi navedene odgovarajuće komore,
Use of a compound having the structure shown in claim 1 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating a disease or disorder selected from breast cancer, multiple myeloma, glioblastoma, and lymphoma. 
Uporaba spoja prema zahtjevu 1, ili njegove farmaceuiski prihvatljive soli, naznačena time, da je za proizvodnju lijeka za liječenje bolesti ili poremećaja povezanih sa nekontroliranim, nenormalnim i/ili neželjenim staničnim djelovanjima.
The apparatus of claim 1, wherein, when the intra prediction mode is a planar mode, the prediction block generator generates the prediction block using a corner reference pixel, a left reference pixel and an upper reference pixel. 
Uređaj iz zahtjeva 1, pri čemu se, kada je intrapredikcijski režim planarni režim, jedinica intrapredikcijskog predviđanja (150) generira prediskcijski blok pomoću kutnog referentnog piksela, lijevog referentnog piksela i gornjeg referentnog piksela.
Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. 
Ukoliko nije drukčije definirano, svi ovdje korišteni tehnički i znanstveni izrazi imaju isto značenje kako se inače podrazumijeva u struci na koju se ovaj izum odnosi.
The method of claim 99, wherein said bile acid sequestrant is colesevelam. The method of claim 99, wherein said insulin is bolus insulin, basal insulin, or an analogue thereof. 
(ili) navedeni sekvestrant žučne kiseline je kolesevelum; ili (iv) navedeni inzulin je bolus inzulin, bazni inzulin ili njegov analog.
A polypeptide for use according to any one of claims 1-2 wherein the treatment is by oral, parenteral, rectal, inhalation or insufflation administration. 
Polipeptid za uporabu, sukladno zahtjevima 1-2, naznačen time, da tretman započinje oralnim putem, parenteralnim putem, rektalnim putem, imhalacijom ili upubivanjem.
A nucleic acid construct, expression vector or host cell expressing a recombinant staphylococcal clumping factor A (ClfA) according to SEQ ID No. 1 or a sequence with at least 85%, preferably at least 95% sequence identity to the sequence of SEQ ID No. 1 or fragment thereof comprising at least amino acid residues 221 to 531 of the fibrinogen binding region (Region A), with at least one amino acid residue substitution or deletion at amino acid residue Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 and/or Val527 to result in a recombinant fibrinogen binding protein with reduced ability or lacking the ability to non-covalently bind fibrinogen which stimulates a greater immune response that the wild type ClfA protein, for use in the treatment or prophylaxis of Staphylococcal infections. 
HR P20161305 T1 15. Konstrukt nukleinske kiseline, vektor ekspresije ili stanica domaćin koji eksprimiraju rekombinantni stafilokokni faktor grudanja A (CIA) prema SEQ ID No. 1 ili sekvenci s barem 85%, poželjno barem 95% identičnosti sekvence u odnosu na SEQ ID No. 1 ili njegov fragment koji obuhvaća barem aminokiselinske ostatke 221 do 531 fibrinogen vezujuće regije (Regija A), s barem jednom supstitucijom ili delecijom aminokiselinskog ostatka na aminokiselinskom ostatku Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 i/ili Val527 da se dobije rekombinantni fibrinogen vezujući protein sa smanjenom sposobnosti ili bez sposobnosti nekovalentnog vezanja fibrinogena što će stimulirati veći imuni odgovor od divljeg tipa CIfA proteina, za uporabu u liječenju ili prevenciji stafilokoknih infekcija.
Figure 7 shows plasma bioactivity for six of the seven samples. 
Slika 7 - pokazuje bioaktivnost plazme za šest od sedam uzoraka.
The method of claim 8, wherein the context set index indicating one of a plurality of context sets used in entropy encoding and decoding of the second critical value flag is set to be the same as a context set index for determining a context set used in entropy encoding and decoding of the first critical value flag. 
pribavljanje (2530) kontekstnog pomaka upotrebljavanog u entropijskom dekodiranju indikatora prve kritične vrijednosti na osnovi broja prethodnih koeficijenata transformacije sa slijedećom ls; te pribavljanje (2540) indeksa konteksta koji označava kontekst upotrebljavan u entropijskom dekodiranju indikatora prve kritične vrijednosti upotrebom indeksa skupa konteksta i kontekstnog pomaka,
In a 100 mL flask fitted with reflux cooler, thermometer and magnetic stirrer, 2.77 g (8.6 mmol) of 2,2′-dithio-diisosorbide (10) obtained according to Example 8 are dissolved in 17 mL of acetic acid and 3.5 mL of acetic anhydride are added. 
U tikvici od 100 mL, opremljenoj s povratnim hladilom, termometrom i magnetskom mješalicom, 2,77 g (8,6 mmolova) 2,2'-ditio-diizo-sorbida (10) dobivenog prema primjeru 8 se otopi u 17 mL octene kiseline 1 doda se 3,5 mL octenog anhidrida.
A process for producing a pyridyl-triazolopyrimidine derivative represented by the formula (I-1) or its salt: wherein 
Postupak za proizvodnju piridil-triazolopirimidin derivata predstavljen formulom (I-1), ili njegova sol,
wherein the method results in a cumulative log10 reduction factor for steps (a), (c) and (c2) of at least 15 with respect to enveloped viruses. 
pri čemu metoda rezultira kumulativnim log10 faktorom smanjenja za korake (a), (c) i (c2) od barem 15 u odnosu na viruse u ovojnici.
The ship according to claim 1 or claim 2, characterized by the fact that each of these deflector members (1) consists of a case closed on the sides by lateral vertical walls. 
Brod prema zahtjevima 1 i 2, naznačen time da se svaki od elemenata za skretanje (1) sastoji od kućišta zatvorenog sa strane bočnim okomitim stjenkama.
(A1f) a phenyl-substituted lower alkoxy group having a halogen-substituted lower alkoxy group(s) as a substituent(s) on a phenyl group), or a pyperazyl group represented by the general formula (A2): 
(A1f) fenil-supstituiranu skupinu niži alkoksi s halogen-supstituiranom skupinom (skupinama) niži alkil kao supstitucntom (supstitucntima) na fenilnoj skupini), ili pipcrazilnu skupinu prikazanu općom formulom (A2):
“Alkyl” means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain. 
"alkil" znači alifatska ugljikovodična skupina koja može biti nerazgranata ili razgranata i sadrži 1 do 20 atoma ugljika u lancu;
said rifamycin SV comprises from about 20% to about 60% by weight of the total weight of said composition; 
Farmaceutski pripravci prema prethodnim patentnim zahtjevima, u kojima je količina sadržanog rifamicina SV od 20 do 90 % masenog udjela.
The liquid pharmaceutical composition according to claim 1, wherein (c) and (d), together, is a combination which is selected from the group consisting of 
Farmaceutski sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da spomenuta farmaceutski prihvatljiva sol adicijske kiseline od trazodona je hidroklorid.
Method according to claim 1, wherein the mutation at the EGFR gene to be detected is selected from the group consisting of: ELREA deletions at the exon 19 and the L858R mutation at the exon 21. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što mutacija u EGFR genu koju treba detektirati se bira iz skupine koju čine: delecije ELREA u egzonu 19, mutacija L858R u egzonu 21 i mutacija T790M.
The system of claim 1, wherein the mobile suction means is operatively coupled to the propelling means by a flexible cord, rope, line, cable, string, or a combination thereof. 
Sustav prema bilo kojem prethodnom zahtjevu, naznačen time što spojna sredstva (5) obuhvaćaju savitljivi kabel, uže, vod, kabel, konop ili njihovu kombinaciju.
PCR primers for cloning mouse heavy VH Name 
Početnice za PCR za kloniranje mišjeg teškog VH Naziv
In one aspect, the invention relates to a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5 or a variant of said amino acid sequence. 
Peptid sukladno patentnom zahtjevu 1, sastavljen od aminokiselinske sekvence odabranu iz skupine sastavljene od SEK ID BR: 3, 41 5.
Use of an efflux protein inhibitor to improve the bioavailability of a renin inhibitor, wherein the renin inhibitor is a δ-amino-y-hydroxy-w-aryl-alkanoic acid amide derivative, or a pharmaceutically acceptable salt thereof, and wherein the efflux protein inhibitor is a MDR1 inhibitor. 
Uporaba inhibitora istjecanja proteina u poboljšanju bioraspoloživosti inhibitora renina, naznačena time, da inhibitor renina je derivat amida 8-amino-y-hidroksi-Q-aril-alkanoične kiseline ili njegova farmaceutski prihvatljiva sol, te pri čemu inhibitor istjecanja proteina je inhibitor MDRI.
The PC is of conventional type and therefore it is very easy to load software of commercial type as well as the developed one. 
PC je konvencionalnog tipa i stoga je vrlo lako učitati neki softver komcrcijalnog tipa kao i onaj softvcr koji je razvijen.
repeating steps (a) and (b), wherein the source basin is used as the recipient basin and the recipient basin is used as the source basin. 
ponavljanje koraka (a) i (b), pri čemu se izvorni bazen koristi kao prijemni bazen i prijemni bazen se koristi kao izvorni bazen
A VZV gE antigen for use according to claim 6, wherein the VZV gE antigen is delivered in a prime boost approach after the live attenuated VZV. 
VZV antigen gE namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što se VZV antigen gE unosi u pristupu s početnim stimulansom nakon živog oslabljenog VZV.